What's Going On With Vanda Pharmaceuticals Shares Today?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 27 2024
0mins
Should l Buy VNDA?
Source: Benzinga
- Vanda Pharmaceuticals Acquisition Proposal Withdrawn: Future Pak has withdrawn its proposal to purchase Vanda Pharmaceuticals Inc., citing lack of response and rejection of their final offer.
- Stock Performance: Vanda Pharmaceuticals' shares have declined over 9% in the past year, with investors being able to access the stock through Invesco NASDAQ Future Gen 200 ETF QQQS.
- Company's Response: Vanda Pharmaceuticals stated that takeover proposals from Future Pak and Cycle Group undervalued the company, leading to the rejection of these offers by the Board.
- FDA Approval: In April, the FDA approved Vanda Pharmaceuticals' Fanapt tablets for the treatment of manic or mixed episodes associated with bipolar I disorder in adults.
- Current Stock Price: As of the latest check, VNDA shares are trading lower by 1.92% at $5.865.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.780
Low
7.50
Averages
13.63
High
22.00
Current: 6.780
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanda Pharmaceuticals Appoints New Board Member
- New Board Member: Vanda Pharmaceuticals appointed Dr. Charles Duncan to its Board of Directors effective April 22, 2026, increasing the board to seven members, six of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Dr. Duncan brings nearly three decades of experience in biotechnology, having covered over 70 companies as a biotechnology analyst at Cantor Fitzgerald & Co., with a focus on neurology and psychiatry, which is expected to significantly support Vanda's innovative pipeline.
- Strategic Development Opportunity: Dr. Duncan noted Vanda's history of innovation in CNS disorders positions the company well for upcoming product data releases, with impactful data anticipated over the next 12 months, potentially ushering in a new era of growth.
- Commitment to Value Creation: Dr. Duncan's appointment is viewed as a strategic investment in Vanda's mission to meet patient needs and create shareholder value, indicating the company's dedication to enhancing its market position and growth potential through its innovative product pipeline.
See More
Vanda Pharmaceuticals Appoints New Board Member
- New Board Member: Vanda Pharmaceuticals appointed Dr. Charles Duncan to its Board of Directors on April 22, 2026, increasing the board to seven members, six of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Dr. Duncan brings nearly three decades of experience in biotechnology, having covered over 70 companies as a biotechnology analyst at Cantor Fitzgerald & Co., with a focus on neurology and psychiatry, which is expected to provide valuable insights for Vanda's innovative pipeline.
- Strategic Growth Phase: Dr. Duncan noted that Vanda's history of innovation in CNS disorders and recent approvals of NEREUS™ and BYSANTI™ signify the company entering a new era of growth, with impactful data expected over the next 12 months to drive value creation.
- Commitment to Patient Needs: Dr. Duncan emphasized that his addition will help Vanda create broader stakeholder value while addressing patient needs, reflecting the company's confidence and commitment to future development.
See More
ANAPTYS FINALIZES DIVESTITURE OF FIRST TRACKS BIOTHERAPEUTICS AND NOW FOCUSES SOLELY ON GSK AND VANDA FINANCIAL PARTNERSHIPS
Separation of First Tracks: ANAPTY has completed the separation of its first tracks in biotherapeutics.
Management of Financial Collaborations: The company now exclusively manages financial collaborations with GSK and Vanda.
See More
Vanda Pharmaceuticals Urges FDA to Withdraw Legislative Proposal
- Proposal Details: The FDA's FY 2027 Congressional Budget proposal seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review timelines to 10-12 months, which could delay patient access to new medications.
- Vanda's Position: Vanda Pharmaceuticals argues that this change would exacerbate review delays, reduce transparency, and increase risks for small innovators, with CEO Mihael H. Polymeropoulos emphasizing that the FDA should comply with existing laws rather than seek to amend them to allow for slower reviews.
- Legal Context: Vanda highlights that federal courts have ruled the FDA's practice of exceeding the 180-day timeline as unlawful, and the agency currently takes up to two months just to decide whether to file an application, raising concerns about the proposal's implications.
- Industry Impact: The proposal could lead to longer wait times for patients to access new drugs and greater uncertainty for biotech innovators, prompting Vanda to urge FDA Commissioner Dr. Marty Makary to withdraw the provision and call on Congress to reject it.
See More
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's proposal in the FY 2027 budget seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review times to 10 to 12 months, which could lead to longer waits for patients needing medications.
- Review Process Changes: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially reducing transparency and increasing financial risks and uncertainties for small innovative companies like Vanda.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, yet the proposal aims to legalize these delays, indicating a disregard for the law.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject legislation that could harm patient interests and stifle innovation.
See More
Vanda Pharmaceuticals Appoints New Board Member
- New Board Member: Vanda Pharmaceuticals appointed Dr. Charles Duncan to its Board of Directors effective April 22, 2026, increasing the board to seven members, six of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Dr. Duncan brings nearly three decades of experience in biotechnology, having covered over 70 companies as a biotechnology analyst at Cantor Fitzgerald & Co., with a focus on neurology and psychiatry, which is expected to significantly support Vanda's innovative pipeline.
- Strategic Development Opportunity: Dr. Duncan noted Vanda's history of innovation in CNS disorders positions the company well for upcoming product data releases, with impactful data anticipated over the next 12 months, potentially ushering in a new era of growth.
- Commitment to Value Creation: Dr. Duncan's appointment is viewed as a strategic investment in Vanda's mission to meet patient needs and create shareholder value, indicating the company's dedication to enhancing its market position and growth potential through its innovative product pipeline.
See More
Vanda Pharmaceuticals Appoints New Board Member
- New Board Member: Vanda Pharmaceuticals appointed Dr. Charles Duncan to its Board of Directors on April 22, 2026, increasing the board to seven members, six of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Dr. Duncan brings nearly three decades of experience in biotechnology, having covered over 70 companies as a biotechnology analyst at Cantor Fitzgerald & Co., with a focus on neurology and psychiatry, which is expected to provide valuable insights for Vanda's innovative pipeline.
- Strategic Growth Phase: Dr. Duncan noted that Vanda's history of innovation in CNS disorders and recent approvals of NEREUS™ and BYSANTI™ signify the company entering a new era of growth, with impactful data expected over the next 12 months to drive value creation.
- Commitment to Patient Needs: Dr. Duncan emphasized that his addition will help Vanda create broader stakeholder value while addressing patient needs, reflecting the company's confidence and commitment to future development.
See More
ANAPTYS FINALIZES DIVESTITURE OF FIRST TRACKS BIOTHERAPEUTICS AND NOW FOCUSES SOLELY ON GSK AND VANDA FINANCIAL PARTNERSHIPS
Separation of First Tracks: ANAPTY has completed the separation of its first tracks in biotherapeutics.
Management of Financial Collaborations: The company now exclusively manages financial collaborations with GSK and Vanda.
See More
Vanda Pharmaceuticals Urges FDA to Withdraw Legislative Proposal
- Proposal Details: The FDA's FY 2027 Congressional Budget proposal seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review timelines to 10-12 months, which could delay patient access to new medications.
- Vanda's Position: Vanda Pharmaceuticals argues that this change would exacerbate review delays, reduce transparency, and increase risks for small innovators, with CEO Mihael H. Polymeropoulos emphasizing that the FDA should comply with existing laws rather than seek to amend them to allow for slower reviews.
- Legal Context: Vanda highlights that federal courts have ruled the FDA's practice of exceeding the 180-day timeline as unlawful, and the agency currently takes up to two months just to decide whether to file an application, raising concerns about the proposal's implications.
- Industry Impact: The proposal could lead to longer wait times for patients to access new drugs and greater uncertainty for biotech innovators, prompting Vanda to urge FDA Commissioner Dr. Marty Makary to withdraw the provision and call on Congress to reject it.
See More
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's proposal in the FY 2027 budget seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review times to 10 to 12 months, which could lead to longer waits for patients needing medications.
- Review Process Changes: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially reducing transparency and increasing financial risks and uncertainties for small innovative companies like Vanda.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, yet the proposal aims to legalize these delays, indicating a disregard for the law.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject legislation that could harm patient interests and stifle innovation.
See More
